BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
Nanobiotix is a clinical stage biotechnology company focused on the development of NBTXR3.
NBTXR3 employs its mechanism as an enhancer of radiation along with downstream immune priming to induce both a local and systemic effect on cancer cells. NBTXR3’s mechanism allows for potential treatment across all solid tumors, with patients enrolled in studies evaluating NBTXR3 effect in HNSCC, HCC, Pancreatic cancer, Esophogeal Cancer, Rectal Cancer, Lung mets, Liver mets, and Sarcoma. NBTXR3’s immune priming also enables synergy with Anti-PD-(L)1 and other immune checkpoint inhibitors.
Nanobiotix received Fast Track Designation for HNSCC in 2020, and plans to launch a pivotal phase III trial in HNSCC in 2021. In 2019 NBTXR3 was granted marketing authorization in Europe in the indication of Soft Tissue Sarcoma.
Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany